2011年1月14日,美国食品和药品管理局(FDA)对医护人员和患者发布安全警告:决奈达隆(dronedarone)可能引起罕见但严重的肝损害[1]。决奈达隆属于抗心律失常药物,于2009年7月经FDA批准上市,之后在欧洲上市。决奈达隆是苯并呋喃衍生物,电生理特性与胺碘酮相近,但不含碘,因此可避免与碘成分相关的不良反应。决奈达隆为口服片剂,通过降低窦房结的自律性、减慢 On January 14, 2011, the U.S. Food and Drug Administration (FDA) issued a safety warning to health care workers and patients that dronedarone may cause rare but severe liver damage [1]. Dronedarone, an antiarrhythmic drug, was approved by the FDA in July 2009 and then went on sale in Europe. Dronedarone, a benzofuran derivative, has similar electrophysiological properties to amiodarone but does not contain iodine, thus avoiding adverse reactions associated with iodine components. Dronedarone is an oral tablet that slows down by reducing the self-regulation of the sinus node